In this issue:
ATTAIN-1: orforglipron (oral GLP-1 RA) for obesity
Genetic predictors of weight loss & side effects with GLP1 RAs
BELIEVE: lean mass with semaglutide ± bimagrumab for obesity
Semaglutide + CBT for alcohol use disorder with comorbid obesity
Global obesity trends 1980–2024
FLEX-SEMA: real-world use of semaglutide
Patient perceptions of weight-related discussions 2022–24
GLP-1 RAs vs. metabolic/bariatric surgery
ODDS: adult weight trajectories & mortality
SURMOUNT: atherosclerotic CV disease risk with BMI <25 kg/m2
Please login below to download this issue (PDF)